about
Synthesis and physicochemical characteristics of a liver-targeted conjugate of fluorodeoxyuridine monophosphate with lactosaminated human albumin.Inhibition of lactate dehydrogenase activity as an approach to cancer therapy.Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug.Lactosaminated human albumin, a hepatotropic carrier of drugs.NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases.Albumin-drug conjugates in the treatment of hepatic disorders.Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment.Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors.Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes.Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells.Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase.Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2',2'-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine.Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor.Altered glycosylation profile of purified plasma ACT from Alzheimer's diseaseFloxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases.Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier.A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate.Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose.Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors.Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A.Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells.LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells.The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cellsCoupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albuminA conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation gradeDoxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosisEnhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-L-lysine coupling: implications for regional chemotherapy of hepatic micrometastasesRad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cellsThe pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albuminAlpha 2,6 sialylation of N-acetyllactosaminic sequences in human colorectal cancer cell lines. Relationship with non-adherent growthIncreased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissuesAdenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effectsA conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver
P50
Q33194855-FE0C73BE-BE71-4A48-B055-8718B001ABCDQ35122361-B5AF7A77-0134-44C9-8B91-21C52A8130ECQ37255427-7175B3CD-B4A1-480F-87F6-4D7F2C974982Q37733849-3D91698B-7167-4550-96DD-5CA80BA4E041Q38156476-22A20995-F28C-4FB4-9D5C-D2DAA204D880Q38207699-4E7DFD85-234D-469C-AAD8-B96291ED4C7DQ38800732-32BBC013-B307-42BE-B4F4-8B210D84C282Q38859786-E2A5282C-854E-42BB-B78B-1525BAE9A063Q38880369-F59404BC-7B15-41DD-AAE7-082C4A4311CDQ39135553-21A3F201-114C-4276-82C8-6166DA3F3D93Q39396436-7CBB4F20-D652-41BC-8BC8-CE882641A873Q39448204-56B24CB0-C9B8-4A81-9C98-FA196D72D54CQ39472703-FEF0F93E-2EEC-455A-A7CB-643597A9E568Q39618478-1CEC53EB-0B16-4D6F-948A-CC994A7CA314Q39668830-8CAAE264-3BC8-4C1B-92C8-456267B3C335Q40967555-5F734CB9-0A64-4C2A-A372-DFBEC217A558Q41682704-B041420A-10D3-4740-B9B7-1957297D71F1Q42577150-71085C9A-B4F3-4A03-956C-1DBDEFD81973Q44073515-C163DFFA-531F-4A56-B3A2-3F982F70CD59Q44516933-86F016C6-6158-42B5-A961-2B4A8A4509C2Q45164861-85978672-6FFB-4957-BE02-ED9D11E92490Q45789839-BC04482F-D3AD-4375-946C-8F9C05D105F7Q46584634-667E7167-B056-4212-B75D-82985F3B65F8Q46604004-9328F375-570E-4D9C-9F48-16CEB9A9C8AEQ47906276-62F018CA-960B-4DF1-B7B1-900E2DAA636BQ48053265-C3B8057A-BC82-4189-B9AF-C13B5C2F9AE2Q48838648-844317EE-86A2-4010-BF45-1A8E1755F5FBQ50587916-DAC80B20-629F-47BF-BA64-37D301C96883Q51003744-A34DAE51-BBD6-4A3B-B2F1-5B4348D27572Q56341474-1C70A972-EF8C-4F17-B98F-94F2C1EA9404Q56995872-8DC4CBBF-7832-40AA-A342-45F6B5549513Q56997657-F7AE081D-0D07-4C28-BE06-EA05FFB757FAQ56998020-DA234488-9E0F-4FF0-878C-CB38C8C62875Q57010945-5405DFB2-32CF-4FE9-A61D-92337087C715Q64388103-85FFBAA8-9EA3-44FD-9291-76244705759FQ67590474-2EAC81BF-8C21-4466-888F-10BDDAAD8A4BQ67982709-192418A7-9445-4AD3-960F-19472B447109Q69099477-EBD5F80D-BB1D-4258-9C0E-6B8D8DB9D0E7Q71150536-56B8845E-F4C5-404D-BE9A-B73F50BAA3CDQ71613960-D99213B5-D8F1-4CC3-9AF5-156D385DAC24
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppina Di Stefano
@ast
Giuseppina Di Stefano
@en
Giuseppina Di Stefano
@es
Giuseppina Di Stefano
@nl
type
label
Giuseppina Di Stefano
@ast
Giuseppina Di Stefano
@en
Giuseppina Di Stefano
@es
Giuseppina Di Stefano
@nl
prefLabel
Giuseppina Di Stefano
@ast
Giuseppina Di Stefano
@en
Giuseppina Di Stefano
@es
Giuseppina Di Stefano
@nl
P106
P21
P31
P496
0000-0003-0375-0176